Coherus Oncology, Inc. has completed a public offering of 28.6 million shares of common stock at $1.75 per share, generating approximately $50.1 million in gross proceeds. The offering was led by established healthcare-focused investors including Janus Henderson, HBM Healthcare Investments, and Samsara BioCapital, reflecting confidence in the company's strategic direction.
The biopharmaceutical company intends to allocate the capital toward multiple initiatives, including supporting the commercial launch and market expansion of LOQTORZI (toripalimab-tpzi), its approved oncology therapeutic. Additional funds will be directed toward advancing clinical development of pipeline candidates and addressing general corporate operational needs.
The capital raise follows Coherus Oncology's efforts to establish its commercial presence in the oncology space. The company's dual focus on commercializing existing assets while progressing earlier-stage development programs positions it to execute across multiple value-creation drivers in the near to medium term.